https://www.bruneihealthwire.com/article/914670072-powerful-oral-steroids-for-cutting-cycles-2026-crazy-bulk-launches-effective-cutting-steroid-stacks-for-strength-and-muscle-growth Brunei Health Wire en PressRelease 2026-05-23T18:49:09+00:00 Powerful Oral Steroids for Cutting Cycles 2026: Crazy Bulk Launches Effective Cutting Steroid Stacks for Strength and Muscle Growth https://ml.globenewswire.com/media/61ecb401-e205-49f0-89a6-a99ba800fcaa/medium/crazybulk.png https://www.bruneihealthwire.com/article/914627424-heallexa-launches-ai-powered-healthcare-directory-with-over-6-million-provider-profiles-to-make-finding-and-booking-care-more-convenient Brunei Health Wire en PressRelease 2026-05-23T13:31:00+00:00 Heallexa Launches AI Powered Healthcare Directory With Over 6 Million Provider Profiles to Make Finding and Booking Care More Convenient https://pressranger.s3.us-west-1.amazonaws.com/3309426/HL.png https://www.bruneihealthwire.com/article/914548444-dempster-therapeutic-services-launches-chicago-speech-therapy-and-polski-logopeda-digital-storefronts-with-instant-online-booking-patient-portal Brunei Health Wire en PressRelease 2026-05-23T04:48:00+00:00 Dempster Therapeutic Services Launches “Chicago Speech Therapy” And “Polski logopeda” Digital Storefronts With Instant Online Booking, Patient Portal, And Rapid Access To Award-Winning Speech Therapy Services https://pressranger.s3.us-west-1.amazonaws.com/3307140/ZocDoc-Award-2026-BRANDED.png https://www.bruneihealthwire.com/article/914491699-roota-hair-growth-roll-on-scalp-serum-roota-hair-activator-spray-under-investigation-evaluating-the-clinically-tested-hair-care-formula-s-claims Brunei Health Wire en PressRelease 2026-05-23T00:33:12+00:00 Roota Hair Growth Roll-On Scalp Serum & Roota Hair Activator Spray Under Investigation: Evaluating the Clinically-Tested Hair Care Formula's Claims https://zingfast.com/wp-content/uploads/2026/05/Roota-Hair-Growth-Roll-On-Scalp-Serum.jpg https://www.bruneihealthwire.com/article/914473691-organifi-parasite-cleanse-kit-the-most-effective-herbal-parasite-binding-detox-supplements-on-the-market Brunei Health Wire en PressRelease 2026-05-22T22:55:19+00:00 Organifi Parasite Cleanse Kit: The Most Effective Herbal Parasite Binding Detox Supplements on the Market https://zingfast.com/wp-content/uploads/2026/05/Organifi-Parasite-Cleanse-Kit.jpg https://www.bruneihealthwire.com/article/914464327-slim-tide-under-investigation-critical-research-details-ingredients-effectiveness-for-metabolic-digestive-support Brunei Health Wire en PressRelease 2026-05-22T22:18:30+00:00 Slim Tide Under Investigation: Critical Research Details Ingredients' Effectiveness for Metabolic & Digestive Support https://zingfast.com/wp-content/uploads/2026/05/Slim-Tide-1.jpg https://www.bruneihealthwire.com/article/914455337-calidi-biotherapeutics-provides-required-nyse-american-disclosure Brunei Health Wire en PressRelease 2026-05-22T22:00:00+00:00 Calidi Biotherapeutics Provides Required NYSE American Disclosure https://ml.globenewswire.com/media/9e574b79-be62-4805-a4b4-cb0b7dcc5fbd/small/calidibiotherapeutics-logo-2x-jpg.jpg https://www.bruneihealthwire.com/article/914455361-glycopulse-claims-evaluated-most-advanced-blood-sugar-support-ingredients-for-healthy-glucose-management-by-glyco-pulse Brunei Health Wire en PressRelease 2026-05-22T21:41:39+00:00 GlycoPulse Claims Evaluated: Most Advanced Blood Sugar Support Ingredients for Healthy Glucose Management by Glyco Pulse https://zingfast.com/wp-content/uploads/2026/05/GlycoPulse.jpg https://www.bruneihealthwire.com/article/914446110-iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Brunei Health Wire en PressRelease 2026-05-22T21:15:00+00:00 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/d0986bd6-4603-4e31-8ed1-f23b3e123605/small/iovance-jpg.jpg https://www.bruneihealthwire.com/article/914446172-immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-stock Brunei Health Wire en PressRelease 2026-05-22T21:15:00+00:00 Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock https://ml.globenewswire.com/media/b46d5687-65de-44df-81d5-e36f2665d8e7/small/immix-logonew-gray-png.png https://www.bruneihealthwire.com/article/914437208-ultragenyx-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4 Brunei Health Wire en PressRelease 2026-05-22T20:30:00+00:00 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/121a9bda-7a64-41f8-85e8-1693a2dfa977/small/ultragenyx-cmyk-png.png https://www.bruneihealthwire.com/article/914437221-greenwich-lifesciences-announces-receipt-of-nasdaq-notice-regarding-late-form-10-q-filing Brunei Health Wire en PressRelease 2026-05-22T20:30:00+00:00 Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing https://ml.globenewswire.com/media/e0bfd967-b05f-43d2-91b4-d2a5d551df99/small/logo-edited-jpg.jpg https://www.bruneihealthwire.com/article/914437216-scynexis-announces-one-for-eight-reverse-stock-split Brunei Health Wire en PressRelease 2026-05-22T20:15:00+00:00 SCYNEXIS Announces One-for-Eight Reverse Stock Split https://ml.globenewswire.com/media/4171e010-3103-4d21-b1c5-5b1c27927dce/small/scyxprimarysmall-png.png https://www.bruneihealthwire.com/article/914437253-nanobiotix-announces-full-exercise-of-underwriters-over-allotment-option-bringing-gross-proceeds-of-offering-to-approximately-100-million Brunei Health Wire en PressRelease 2026-05-22T20:15:00+00:00 NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.bruneihealthwire.com/article/914437258-nanobiotix-annonce-l-exercice-integral-de-l-option-de-surallocation-portant-le-produit-de-l-offre-a-100-millions-de-dollars Brunei Health Wire en PressRelease 2026-05-22T20:15:00+00:00 NANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.bruneihealthwire.com/article/914437249-xtl-announces-receipt-of-staff-delist-determination-from-nasdaq Brunei Health Wire en PressRelease 2026-05-22T20:10:00+00:00 XTL Announces Receipt of Staff Delist Determination from Nasdaq https://ml.globenewswire.com/media/c90a3187-c398-47d6-a46e-5d3647374681/small/logo-png.png https://www.bruneihealthwire.com/article/914437169-abivax-presents-first-quarter-2026-financial-results-and-reports-three-year-interim-data-from-study-108-a-phase-2a-2b-open-label-extension-trial-of Brunei Health Wire en PressRelease 2026-05-22T20:05:00+00:00 Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.bruneihealthwire.com/article/914437171-abivax-pr-sente-ses-r-sultats-financiers-du-t1-2026-et-les-donn-es-trois-ans-de-l-tude-108-un-essai-d-extension-ouvert-de-phase-2a-2b-valuant Brunei Health Wire en PressRelease 2026-05-22T20:05:00+00:00 Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/ https://www.bruneihealthwire.com/article/914437227-crinetics-pharmaceuticals-to-participate-in-jefferies-global-healthcare-conference-2026 Brunei Health Wire en PressRelease 2026-05-22T20:05:00+00:00 Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 https://ml.globenewswire.com/media/ff5e7cfa-b9fb-4679-8bf3-6e9d25207b83/small/crinetics-logo-trademark-jpg-1-jpg.jpg https://www.bruneihealthwire.com/article/914437234-avalo-therapeutics-announces-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4 Brunei Health Wire en PressRelease 2026-05-22T20:01:00+00:00 Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/950a0fc1-6e06-40b5-9adc-6d3d9f2d5e78/small/avalo-final-black-01-jpg.jpg https://www.bruneihealthwire.com/article/914427965-european-commission-grants-marketing-authorization-to-pharming-s-joenja-leniolisib-the-first-approved-treatment-for-apds-in-the-european-union Brunei Health Wire en PressRelease 2026-05-22T19:30:00+00:00 European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European Union https://ml-eu.globenewswire.com/media/f164672f-d67c-41d2-9c79-46caee419077/small/logo-pharming-original-png.png https://www.bruneihealthwire.com/article/914401229-vaya-health-and-partners-health-management-announce-merger Brunei Health Wire en PressRelease 2026-05-22T17:30:00+00:00 Vaya Health and Partners Health Management Announce Merger https://ml.globenewswire.com/Resource/Download/362e27c4-b9da-40be-b326-0ea7fd8e2887/vaya-health.png https://www.bruneihealthwire.com/article/914401048-scilex-holding-company-scilex-announces-its-board-of-directors-approved-a-dividend-of-semnur-pharmaceuticals-inc-common-stock-to-holders-of Brunei Health Wire en PressRelease 2026-05-22T17:15:00+00:00 Scilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026 https://ml.globenewswire.com/media/e2f985bf-0880-4d05-8838-90a69c888cf9/small/logo-jpg.jpg https://www.bruneihealthwire.com/article/914392734-ai-saved-me-launches-to-document-how-people-are-using-ai-in-everyday-life Brunei Health Wire en PressRelease 2026-05-22T16:51:00+00:00 AI Saved Me Launches to Document How People Are Using AI in Everyday Life https://ml.globenewswire.com/media/b7b85bf8-8304-4292-ba08-61018931bc88/small/ai-saved-me-logo.png https://www.bruneihealthwire.com/article/914392972-tpa-ncpa-applaud-tennessee-law-banning-pbms-from-owning-pharmacies Brunei Health Wire en PressRelease 2026-05-22T16:49:43+00:00 TPA, NCPA Applaud Tennessee Law Banning PBMs from Owning Pharmacies https://ml.globenewswire.com/media/MzA2OGM0OTgtNTM1OS00OGY2LWIzNTgtZTg3ZDRhOWRhY2FhLTExMzczNDEtMjAyNi0wNS0yMi1lbg==/tiny/National-Community-Pharmacists.png https://www.bruneihealthwire.com/article/914393030-medx-holdings-announces-q1-2026-highlights-multi-city-expansion-and-corporate-action-to-rebrand-as-dazed-inc-ticker-daze Brunei Health Wire en PressRelease 2026-05-22T16:47:12+00:00 MEDX HOLDINGS ANNOUNCES Q1 2026 HIGHLIGHTS, MULTI-CITY EXPANSION, AND CORPORATE ACTION TO REBRAND AS DAZED INC. (TICKER: DAZE) https://ml.globenewswire.com/media/995733cb-620f-4ea6-b204-8b5b5689df30/small/medx-logo-jpg.jpg https://www.bruneihealthwire.com/article/914375548-the-newest-name-on-nasdaq-wants-to-help-the-body-rebuild-itself Brunei Health Wire en PressRelease 2026-05-22T15:30:00+00:00 The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself https://ml.globenewswire.com/media/537a8428-aa51-425e-b0c7-625da6b05a49/small/95686-jpg.jpg https://www.bruneihealthwire.com/article/914359172-regenix-labs-introduces-nmn-supplement-designed-to-support-cellular-vitality-and-healthy-aging Brunei Health Wire en PressRelease 2026-05-22T14:00:00+00:00 Regenix Labs Introduces NMN Supplement Designed to Support Cellular Vitality and Healthy Aging https://ml.globenewswire.com/media/8d5a703e-01a1-4502-9218-3e6b056b489d/medium/regenix-labs-a-wellness-focused-company-committed-to-ingredi.png https://www.bruneihealthwire.com/article/914350097-safespace-global-announces-new-senior-living-client-clearview-healthcare-management-expanding-deployment-across-seven-tennessee-facilities Brunei Health Wire en PressRelease 2026-05-22T13:15:00+00:00 SafeSpace Global Announces New Senior Living Client; Clearview Healthcare Management, Expanding Deployment Across Seven Tennessee Facilities https://ml.globenewswire.com/media/e95639ca-a47d-4c90-a44e-cf8a03b6a6d2/small/logo-jpg.jpg https://www.bruneihealthwire.com/article/914350177-agios-pyrukynd-mitapivat-approved-in-the-european-union-for-adults-with-thalassemia Brunei Health Wire en PressRelease 2026-05-22T13:15:00+00:00 Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia https://ml.globenewswire.com/media/c7d64dad-71c8-47cc-a58d-c93a49ce8f01/small/agios-2021-logo-png.png https://www.bruneihealthwire.com/article/914350118-oncolytics-biotech-to-present-data-at-asco-2026-reinforcing-pelareorep-s-potential-across-gastrointestinal-tumors Brunei Health Wire en PressRelease 2026-05-22T13:00:00+00:00 Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors https://ml.globenewswire.com/media/f0121259-b2be-4290-90a3-0d2c3b243aed/small/oncolytics-biotech-jpg.jpg https://www.bruneihealthwire.com/article/914350127-bioage-labs-to-present-at-upcoming-investor-conferences Brunei Health Wire en PressRelease 2026-05-22T13:00:00+00:00 BioAge Labs to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/d6df9eb5-87f7-4e2e-b503-8a7d8651428e/small/bioage-dark-logo-white-bg-500x500-png.png https://www.bruneihealthwire.com/article/914341259-20-20-biolabs-commences-emergency-planning-for-ebola-hantavirus-lab-testing-if-outbreak-creates-overflow-demand Brunei Health Wire en PressRelease 2026-05-22T12:31:00+00:00 20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand https://ml.globenewswire.com/media/bcaf95ca-9983-408c-bc61-646e4ee2f925/small/2020-biolabs-logo-png.png https://www.bruneihealthwire.com/article/914341214-fibrobiologics-presents-preclinical-data-demonstrating-durable-immunomodulation-in-psoriasis-at-the-society-for-investigative-dermatology-2026-annual Brunei Health Wire en PressRelease 2026-05-22T12:30:00+00:00 FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting https://ml.globenewswire.com/media/720fe0fe-52b4-4ccc-a5ad-95d4288f1df2/small/fibrobiologics-logo-2022-jpg.jpg https://www.bruneihealthwire.com/article/914341294-ebola-outbreak-spreading-at-alarming-speed-who-warns-growing-global-health-emergencies-highlight-rising-need-for-tomi-s-steramist-technology Brunei Health Wire en PressRelease 2026-05-22T12:30:00+00:00 Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology https://ml.globenewswire.com/media/f8c7c513-0121-4507-84b7-3680626d9cf3/small/tomi-jpg.jpg https://www.bruneihealthwire.com/article/914341229-chmp-issues-positive-opinion-for-jascayd-nerandomilast-bringing-a-new-ipf-and-ppf-therapy-closer-to-patients-in-the-eu Brunei Health Wire en PressRelease 2026-05-22T12:15:00+00:00 CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.bruneihealthwire.com/article/914331661-black-diamond-therapeutics-to-participate-in-jefferies-global-healthcare-conference Brunei Health Wire en PressRelease 2026-05-22T12:00:00+00:00 Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference https://ml.globenewswire.com/media/b8da4d92-789b-4f0a-a1e2-2739af370155/small/bdtxlogo-pantone3135c-png-png.png https://www.bruneihealthwire.com/article/914331685-phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences Brunei Health Wire en PressRelease 2026-05-22T12:00:00+00:00 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/0baa6f51-c6cb-4b21-a4e0-573a18b8171c/small/phathom-pharm-logo-jpg.jpg https://www.bruneihealthwire.com/article/914331686-anavex-life-sciences-receives-expected-nasdaq-delinquency-notification Brunei Health Wire en PressRelease 2026-05-22T12:00:00+00:00 Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification https://ml.globenewswire.com/media/1b0f858f-4f7f-4f50-b691-a25307283fb5/small/anavexlogor-transparent-3x-png.png https://www.bruneihealthwire.com/article/914331787-sbc-medical-and-blez-asia-celebrate-opening-of-new-aesthetic-dermatology-section-at-blez-clinic-in-bangkok Brunei Health Wire en PressRelease 2026-05-22T12:00:00+00:00 SBC Medical and BLEZ ASIA Celebrate Opening of New Aesthetic Dermatology Section at BLEZ CLINIC in Bangkok https://ml.globenewswire.com/media/67e1656f-882c-4c8e-bbb6-13bc2933e270/medium/sbc-medical-and-blez-asia-celebrate-opening-of-new-aesthetic.png https://www.bruneihealthwire.com/article/914331792-2026-asco-pivotal-data-of-innocare-s-novel-bcl2-inhibitor-mesutoclax-released Brunei Health Wire en PressRelease 2026-05-22T12:00:00+00:00 2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released https://ml.globenewswire.com/media/2dc70b00-a0b0-4d85-adef-2717a7067aec/small/innocare-eng-logo-horizontal-png.png https://www.bruneihealthwire.com/article/914331680-briacell-presentations-highlight-positive-clinical-data-for-bria-imt-at-asco-2026 Brunei Health Wire en PressRelease 2026-05-22T11:30:00+00:00 BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026 https://ml.globenewswire.com/media/88b9408d-31d4-4afd-beff-f855719a15d8/small/briacell-logo-square-a-jpg.jpg https://www.bruneihealthwire.com/article/914331684-repligen-corporation-to-present-at-william-blair-46th-annual-growth-stock-conference Brunei Health Wire en PressRelease 2026-05-22T11:30:00+00:00 Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg https://www.bruneihealthwire.com/article/914322031-assembly-biosciences-announces-pricing-of-100-million-offering-of-common-stock-and-pre-funded-warrants Brunei Health Wire en PressRelease 2026-05-22T11:05:00+00:00 Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/33089548-b62b-412d-9343-ae38d8b720c6/small/assemblybio-logo-rgb-png.png https://www.bruneihealthwire.com/article/914321207-ac-immune-presents-new-phase-1-data-indicating-higher-uptake-of-tdp-43-pet-tracer-aci-19626-in-patients-with-als Brunei Health Wire en PressRelease 2026-05-22T11:00:00+00:00 AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS https://ml-eu.globenewswire.com/media/0065cdfd-b9fc-4994-8aca-731c1d031b51/small/logo-jpg.jpg https://www.bruneihealthwire.com/article/914321585-cartigenix-hp-backed-by-three-human-studies-as-clinicians-seek-evidence-based-joint-health-options Brunei Health Wire en PressRelease 2026-05-22T11:00:00+00:00 Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options https://ml.globenewswire.com/media/d7dc39f8-a2af-4bdc-8746-60a8c4c3ddc8/small/calroy-health-sciences-logo-rachel-rowley-png.png https://www.bruneihealthwire.com/article/914321642-otarmeni-lunsotogene-parvec-receives-ema-filing-acceptance-for-genetic-hearing-loss Brunei Health Wire en PressRelease 2026-05-22T11:00:00+00:00 Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.bruneihealthwire.com/article/914321718-enable-injections-announces-ce-certification-of-the-enfuse-on-body-delivery-system-for-use-with-aspaveli-distributed-by-sobi Brunei Health Wire en PressRelease 2026-05-22T11:00:00+00:00 Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi https://ml.globenewswire.com/media/f41706a5-9f61-4772-83f1-6aa50c660788/small/enable-injections-logo-png.png https://www.bruneihealthwire.com/article/914321794-biostem-technologies-announces-2-5-million-private-placement-financing-with-its-first-institutional-investor Brunei Health Wire en PressRelease 2026-05-22T11:00:00+00:00 BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor https://ml.globenewswire.com/media/da0ea21a-fd6e-425a-a8f2-6f69dc2b4612/small/biostem-main-logo-png.png https://www.bruneihealthwire.com/article/914321796-assembly-biosciences-announces-expansion-of-abi-6250-clinical-development-into-cholestatic-liver-diseases Brunei Health Wire en PressRelease 2026-05-22T11:00:00+00:00 Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases https://ml.globenewswire.com/media/33089548-b62b-412d-9343-ae38d8b720c6/small/assemblybio-logo-rgb-png.png https://www.bruneihealthwire.com/article/914321886-medicenna-announces-the-filing-of-its-prospectus-supplement-and-investment-term-sheet Brunei Health Wire en PressRelease 2026-05-22T11:00:00+00:00 Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet https://ml.globenewswire.com/media/7e312e67-9924-4773-b548-47ed05d54904/small/new-logo-small-png.png https://www.bruneihealthwire.com/article/914321869-arch-biopartners-announces-royal-columbian-hospital-has-dosed-its-first-patient-in-its-phase-ii-cardiac-surgery-associated-aki-trial Brunei Health Wire en PressRelease 2026-05-22T10:50:00+00:00 Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial https://ml.globenewswire.com/media/8fae7e83-0899-4bbc-ba40-0250cdb9aea7/small/logo-png.png https://www.bruneihealthwire.com/article/914295860-biontech-pr-sentiert-auf-der-asco-jahrestagung-2026-fortschritte-aus-pipelineprogrammen-in-der-sp-ten-klinischen-entwicklung Brunei Health Wire en PressRelease 2026-05-22T09:00:00+00:00 BioNTech präsentiert auf der ASCO-Jahrestagung 2026 Fortschritte aus Pipelineprogrammen in der späten klinischen Entwicklung https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.bruneihealthwire.com/article/914295902-biontech-to-showcase-progress-across-late-stage-oncology-pipeline-at-the-2026-asco-annual-meeting Brunei Health Wire en PressRelease 2026-05-22T09:00:00+00:00 BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.bruneihealthwire.com/article/914280549-china-approves-hernexeos-as-first-targeted-oral-treatment-option-for-her2-mutant-advanced-nsclc-at-initial-diagnosis Brunei Health Wire en PressRelease 2026-05-22T07:45:00+00:00 China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis https://ml-eu.globenewswire.com/media/f121dfae-77e7-4a01-b1ef-6b757767ddab/small/111boehringer-ingelheim-logo-rgb-dark-green-002-png.png https://www.bruneihealthwire.com/article/914280532-storm-therapeutics-to-present-promising-phase-1-sarcoma-data-demonstrating-activity-of-first-in-class-mettl3-inhibitor-stc-15-at-asco-2026 Brunei Health Wire en PressRelease 2026-05-22T07:30:00+00:00 STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026 https://ml-eu.globenewswire.com/media/1f159389-0c23-4305-b40e-b83e89274cee/small/logo-png.PNG https://www.bruneihealthwire.com/article/914264116-hanmi-pharmaceutical-se-asocia-con-organon-para-exportar-terapias-combinadas-al-sudeste-asi-tico Brunei Health Wire en PressRelease 2026-05-22T06:20:18+00:00 Hanmi Pharmaceutical se asocia con Organon para exportar terapias combinadas al Sudeste Asiático https://ml.globenewswire.com/media/526a18fe-e048-4862-91e5-0a6effeaf8ab/small/hanmi-pharmaceutical-logo-jpg.jpg https://www.bruneihealthwire.com/article/914264215-hanmi-pharmaceutical-faz-parceria-com-a-organon-para-exporta-o-de-terapias-de-combina-o-para-o-sudeste-asi-tico Brunei Health Wire en PressRelease 2026-05-22T06:20:18+00:00 Hanmi Pharmaceutical Faz Parceria com a Organon para Exportação de Terapias de Combinação para o Sudeste Asiático https://ml.globenewswire.com/media/526a18fe-e048-4862-91e5-0a6effeaf8ab/small/hanmi-pharmaceutical-logo-jpg.jpg https://www.bruneihealthwire.com/article/914264043-angel-introduces-x2-water-filter-system-with-advanced-tankless-7-stage-filtration-and-99-pfas-reduction Brunei Health Wire en PressRelease 2026-05-22T05:45:33+00:00 ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction https://ml.globenewswire.com/media/38ebd348-2161-4e2e-bd81-b7e8c6fd5324/medium/image-1.jpeg https://www.bruneihealthwire.com/article/914263955-ose-immunotherapeutics-annonce-les-r-sultats-de-topline-positifs-de-l-tude-de-phase-2-tedova-de-tedopi-dans-le-cancer-de-l-ovaire-en-rechute Brunei Health Wire en PressRelease 2026-05-22T05:30:00+00:00 OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ https://www.bruneihealthwire.com/article/914263967-ose-immunotherapeutics-reports-positive-topline-results-of-tedova-phase-2-trial-with-tedopi-in-recurrent-ovarian-cancer Brunei Health Wire en PressRelease 2026-05-22T05:30:00+00:00 OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer https://ml-eu.globenewswire.com/media/e79ae2c6-fc13-4a02-9759-4ecc9c4fdb22/small/ose-logo-horizontal-rvb-png.png https://www.bruneihealthwire.com/article/914242935-nervgen-announces-pricing-of-us-60-0-million-public-offering-of-securities Brunei Health Wire en PressRelease 2026-05-22T03:27:00+00:00 NervGen Announces Pricing of US$60.0 Million Public Offering of Securities https://ml.globenewswire.com/media/bb42d0ef-06b6-4b90-8389-ca991092aa37/small/nervgen-logo-updated-globenewswire-png.png https://www.bruneihealthwire.com/article/914218852-medline-inc-announces-pricing-of-upsized-secondary-offering-of-class-a-common-stock Brunei Health Wire en PressRelease 2026-05-22T02:45:00+00:00 Medline Inc. announces pricing of upsized secondary offering of Class A common stock https://ml.globenewswire.com/media/70e45830-32e3-4232-b15b-7e43c436de41/small/log-medline-1200-630-center-png.png https://www.bruneihealthwire.com/article/914218482-femicore-claims-evaluated-investigating-the-ingredients-for-bladder-support-femi-core-consumer-complaints-exposed Brunei Health Wire en PressRelease 2026-05-22T01:24:10+00:00 FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed https://zingfast.com/wp-content/uploads/2026/05/FemiCore.jpg https://www.bruneihealthwire.com/article/914218418-most-effective-magnesium-pain-cream-researched-real-magnesium-niacinamide-relief-for-peak-health-nerve-pain-recovery Brunei Health Wire en PressRelease 2026-05-22T01:05:27+00:00 Most Effective Magnesium Pain Cream Researched: Real Magnesium Niacinamide Relief for Peak Health & Nerve Pain Recovery https://zingfast.com/wp-content/uploads/2026/05/Best-Magnesium-Pain-Cream.jpg https://www.bruneihealthwire.com/article/914190921-liminatus-pharma-announces-nasdaq-delisting-notification Brunei Health Wire en PressRelease 2026-05-22T00:28:26+00:00 Liminatus Pharma Announces Nasdaq Delisting Notification https://ml.globenewswire.com/media/9ad52a99-f6dd-4ecb-8aa0-15713a0e8788/small/picture1-png.png https://www.bruneihealthwire.com/article/914190534-taimed-biologics-completes-phase-2b-enrollment-for-tmb-365-380-in-hiv-maintenance-therapy-study Brunei Health Wire en PressRelease 2026-05-22T00:00:00+00:00 TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study https://ml.globenewswire.com/media/1cb82885-f089-49cf-9399-8f9e4bc0918c/small/taimed-logo-png.png https://www.bruneihealthwire.com/article/914190829-hutchmed-highlights-clinical-data-to-be-presented-at-the-2026-asco-annual-meeting Brunei Health Wire en PressRelease 2026-05-22T00:00:00+00:00 HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting https://ml.globenewswire.com/media/085957ad-3bec-49ee-b13e-39961b83c7be/small/hutchmed-small-spaced-1000x305-whitebgd-png.png https://www.bruneihealthwire.com/article/914190865-ascentage-pharma-releases-latest-clinical-data-from-multiple-trials-at-asco-2026 Brunei Health Wire en PressRelease 2026-05-22T00:00:00+00:00 Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 https://ml.globenewswire.com/media/b9623a51-a13b-4b80-8152-61d5014f4a0a/small/2025-11-12-ascentage-600x600-png.png